Cipla: Capturing the Global AIDS Drugs Market |
ICMR HOME | Case Studies Collection Please note: This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source. |
||||
Excerpts
GlobalizationIndia's leading pharmaceutical companies aggressively looked for overseas markets. Cipla was no exception. Cipla's exports for the financial year ended March 31, 2003 amounted to Rs.5,660 million. The company's manufacturing facilities had been approved by various regulatory authorities including, Food and Drug Administration (FDA), USA, Medicines Control Agency (MCA), UK, Therapeutic Goods Administration (TGA), Australia, Medicines Control Council (MCC), South Africa, National Institute of Pharmacy (NIP), Hungary, Pharamaceutical Inspection Convention (PIC), Germany, World Health Organization (WHO), State Institute for the Control of Drugs, Slovak Republic and ANVISA, Brazil. Cipla had already filed 11 abbreviated new drug applications (ANDAs) in the US market...
|
Case Studies Links:-
Case Studies,
Short Case Studies,
Simplified Case Studies.
Other Case Studies:-
Multimedia Case Studies,
Cases in Other Languages.
Business Reports Link:-
Business Reports.
Books:-
Textbooks, Work Books, Case Study Volumes.